Stocks · News reference

Wolfe Research Upgrades Biogen to Outperform, Announces $300 Price Target

Aug 13, 2026, 5:18 PMBenzinga Newsdesk

Wolfe Research analyst Alexandria Hammond upgrades Biogen (NASDAQ:BIIB) from Peer Perform to Outperform and announces $300 price target.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 4, 2026, 8:00 AMBenzinga Newsdesk
Stoke, Biogen Report Lasting Seizure Reductions In Dravet Syndrome Study
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB) today announced presentations
BIIB STOK
BenzingaSep 3, 2026, 5:32 PMBenzinga Newsdesk
Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $245
BIIB
BenzingaSep 3, 2026, 8:06 AMBenzinga Newsdesk
Biogen And Eisai Win China Approval For At-Home Weekly Leqembi Alzheimer’s Treatment
Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB) announced today that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (subcutaneous autoinjector: SC-AI), the
BIIB
BenzingaSep 1, 2026, 11:31 AMBenzinga Newsdesk
Stoke Therapeutics, Biogen Present Data On Zorevunersen As Treatment For Dravet Syndrome At 16th European Epilepsy Congress
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced
BIIB STOK